Several small studies were published evaluating the effect of Endoscopic Gastric Botulinum Toxin type A (EGB) for the treatment of obesity giving conflicting results. Botulinum Toxin type A (BT-A) has a powerful inhibiting effect of long duration on the muscular contractions of smooth and striated muscles. This property has been used in the treatment of digestive illnesses characterized by muscular spasm, particularly achalasia and anal fissure Objectives: The aims of this study are to evaluate the benefit, safety and efficacy of EGB as well as providing recommendations of injection sites in carefully selected patients.


429 patients were studied between December 2012 to December 2018 as a continuation of a previous study. BMI 27-42.Follow up period of 3-12 months and age from 18 to 59.


61% patients continued follow up after 6 months 33% of patients were lose to follow up, 7% of patients requested to repeat the procedure either to help maintain weight lose or to try again with more compliance.17% of patients had 0 – 3kg weight lose - considered failure of procedure. All failed cases were age between 18 –21,73% of patient regained the weight after 12 months. 11% complained of constipation and required laxatives.


Results are comparable to other endoscopic procedures. Safe with no reported major complications. Strict dietary follow up is necessary for desirable outcomes